Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
André F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, Lima JP, Aksoy S, Gavila Gregori J, De Laurentiis M, Bianchini G, Roylance R, Miyoshi Y, Armstrong A, Sinha R, Ruiz Borrego M, Lim E, Ettl J, Yerushalmi R, Zagouri F, Duhoux FP, Fehm T, Gambhire D, Cathcart J, Wu C, Chu C, Egorov A, Krop I. André F, et al. Among authors: armstrong a. Lancet. 2023 May 27;401(10390):1773-1785. doi: 10.1016/S0140-6736(23)00725-0. Epub 2023 Apr 20. Lancet. 2023. PMID: 37086745 Clinical Trial.
PRACTISING PATIENT.
ARMSTRONG A. ARMSTRONG A. Lancet. 1964 Sep 12;2(7359):581-3. doi: 10.1016/s0140-6736(64)90645-2. Lancet. 1964. PMID: 14172368 No abstract available.
MEDICAL MANPOWER.
ARMSTRONG A. ARMSTRONG A. Lancet. 1964 Sep 12;2(7359):584-5. Lancet. 1964. PMID: 14172369 No abstract available.
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Armstrong AJ, Geva R, Chung HC, Lemech C, Miller WH Jr, Hansen AR, Lee JS, Tsai F, Solomon BJ, Kim TM, Rolfo C, Giranda V, Ren Y, Liu F, Kandala B, Freshwater T, Wang JS. Armstrong AJ, et al. Invest New Drugs. 2024 May 20. doi: 10.1007/s10637-024-01444-0. Online ahead of print. Invest New Drugs. 2024. PMID: 38767685 No abstract available.
Conceptual framework for preterm birth review in San Francisco.
Stookey JD, Guendelman S, McCallister B, Whittemore P, Abu-Amara D, Elsasser MA, Dahir F, Armstrong A, Jackson R. Stookey JD, et al. Among authors: armstrong a. Front Public Health. 2024 May 1;12:1332972. doi: 10.3389/fpubh.2024.1332972. eCollection 2024. Front Public Health. 2024. PMID: 38751590 Free PMC article.
Host-derived Interleukin 1α induces an immunosuppressive tumor microenvironment via regulating monocyte-to-macrophage differentiation.
Keerthi Raja MR, Gupta G, Atkinson G, Kathrein K, Armstrong A, Gower M, Roninson I, Broude E, Chen M, Ji H, Lim CU, Wang H, Fan D, Xu P, Li J, Zhou G, Chen H. Keerthi Raja MR, et al. Among authors: armstrong a. bioRxiv [Preprint]. 2024 May 5:2024.05.03.592354. doi: 10.1101/2024.05.03.592354. bioRxiv. 2024. PMID: 38746389 Free PMC article. Preprint.
A Phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.
Hamilton E, Oliveira M, Turner N, García-Corbacho J, Hernando C, Ciruelos EM, Kabos P, Borrego MR, Armstrong A, Patel MR, Vaklavas C, Twelves C, Boni V, Incorvati J, Brier T, Gibbons L, Klinowska T, Lindemann JPO, Morrow CJ, Sykes A, Baird R. Hamilton E, et al. Among authors: armstrong a. Ann Oncol. 2024 May 8:S0923-7534(24)00138-8. doi: 10.1016/j.annonc.2024.04.012. Online ahead of print. Ann Oncol. 2024. PMID: 38729567 Free article.
2,154 results